A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Phase 2 Completed 88 enrolled Tonix Pharmaceuticals, Inc. Premier · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with chronic migraine.

Timeline

Start: 2022-12-06
Primary completion: 2023-10-08
Completion: 2023-10-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxytocin	Peptide	30 iu	Intranasal
Subject	Oxytocin	Peptide	60 iu	Intranasal

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Summary

Timeline

Drugs

Indications